Genmab — Februar 2021
-
Afhænger af regnskabspraksis
-
Lyder som om man venter ofa godkendelse i denne omgang
-
I EU
-
Timeframe for arbitrage - kan blive i 2021, men kan også gå ind i 2022
-
Gen1046 - expansion cohorts. Der kommer noget omkring combination treatments.
-
Men nævner ikke hvor mange cohorts
-
Mim-8 fase 2 kan komme i løbet af året
-
Gen1046 der er stigende aktivitet på området
-
@Vitus, min antagelse af Genmab "hensatte" var forkert. Genmab indregner ikke omsætning vedr. Helo Royalty (ca. 2 % af Dara Royal) fordi salget (omsætningen) ikke kan opgøres og måles pålideligt og uden risiko
-
Epco i cll - evidence of t-cell direction. Concerns about safety. GEN har doseret i fase 1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind